VAXX

Vaxxinity, Inc.

0.12 USD
+0.04 (+46.63%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Vaxxinity, Inc. stock is down -21.8% since 30 days ago. The next earnings date is Jun 11, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 May’s closed higher than April.

About Vaxxinity, Inc.

Vaxxinity, Inc. focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company is developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial. It is also developing an anti-tau product candidate for various neurodegenerative conditions, including AD.